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With the advent of the direct oral anticoagulants (DOACs),
patients requiring anticoagulation for common conditions
such as atrial fibrillation and venous thromboembolism
no longer need to worry about dietary restrictions or
regular monitoring of the international normalized ratio
which complicated warfarin treatment. Switching from
warfarin to apixaban, a DOAC, has been shown to improve
patient satisfaction by reducing treatment burden [1]. The
clotting factor Xa inhibitors (apixaban, rivaroxaban, and
edoxaban) and the direct thrombin inhibitors (argatroban
and dabigatran) have shown non-inferiority in preventing
thromboembolic events and a superior safety profile in
terms of bleeding in several trials when compared to
warfarin [2-6]. Furthermore, apixaban and dabigatran
have even shown superiority in preventing stroke or
systemic embolism [3,6].
Despite these promising outcomes, there remains an
important subgroup of patients who have been excluded
from the initial DOAC trials: advanced chronic kidney
disease (CKD stage 4-5) and hemodialysis (HD) patients.
Specifically, the ARISTOTLE trial evaluating the efficacy
of apixaban versus warfarin in preventing stroke or
systemic embolization in patients with atrial fibrillation
excluded individuals with a serum creatinine greater than
2.5 mg/mL or an estimated GFR less than 25 mL/min
[7]. The AVERROES trial similarly compared apixaban
to warfarin and excluded patients with renal insufficiency
utilizing identical criteria to the ARISTOTLE study
[8]. This population, however, having a high burden of
atrial fibrillation and cardiovascular disease [9,10], is
at increased risk of stroke [11], and would theoretically
benefit greatly from treatment with DOACs.
Concerns regarding the use of oral anticoagulation in
general and with DOACs in particular emerge from two
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perspectives: that of efficacy and that of safety. Available
retrospective studies both with warfarin [12-16] and
with apixaban [17] have yielded conflicting results
with regards to the benefit of anticoagulation in CKD
patients. The differential effect of statins in CKD and
non-CKD populations should serve as a warning against
extrapolating the results of prospective trials that have not
studied the population in question [18]. On the other side
of the problem, the safety of anticoagulation in CKD and
HD patients is an important one given their inherently
higher propensity for bleeding (including with warfarin
[15]) and the impaired clearance of renally-excreted
DOACs in ESRD [19,20]. All DOACs are renally excreted
to some degree and, in the setting of kidney insufficiency,
even properly dosed medications may accumulate in the
body which can increase the risk for major bleeding events
[21]. With one of the lowest percentages of renal clearance
at 27% [22], apixaban may represent one of the safest
choices in CKD patients and two retrospective studies have
found a significantly lower bleeding risk with apixaban
compared to warfarin in the CKD population, which was
not demonstrated with other DOACs [23,24]. Apixaban
dosing in the setting of HD remains controversial. One
pharmacokinetic study showed that a reduced dose of
apixaban at 2.5 mg twice daily in HD patients was found to
predictably result in equivalent drug exposure to a dose of
5 mg twice daily in patients with preserved renal function.
While a full dose of 5 mg twice daily led to supratherapeutic
doses in HD patients [25]. The timing of administration is
also likely to influence drug levels [26]. Others, however,
found no increase in drug levels in HD patients [27,28].
Clinical evidence on the safety and efficacy of apixaban
in CKD and HD patients remains limited as only one
randomized controlled trial has been completed, but
was stopped early. Decisions on DOAC use in this cohort
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must rely primarily on retrospective studies, registry data,
metanalyses, one post-hoc analysis of the ARISTOTLE
trial and one underpowered randomized controlled trial.
Available observational data has shown a consistent trend
of lower bleeding with apixaban compared to warfarin [2931], with one large study demonstrating higher efficacy as
well for the prevention of thrombotic events at doses of 5
mg twice daily [31]. Although prospective in nature, the
ARISTOTLE trial did not include renal function amongst
its randomization variables and any results should be
interpreted as a post-hoc analysis. The study by Stanifer
and colleagues found a lower incidence of bleeding with
apixaban compared to warfarin in patients with creatinine
clearance between 25 and 30 ml/min, with a larger effect
size compared to patients with better renal function [28].
RENAL-AF, the only completed randomized controlled
trial investigating the use of apixaban in HD patients
was unfortunately stopped early due to lack of funding
and low accrual [32]. Out of a planned 760 patients only
154 were included in the final analysis and, as such, the
study remained underpowered and any interpretation
of their findings must be done cautiously. It is, however,
reassuring that even with this limited sample, the
frequency of clinically relevant non-major bleeding was
lower in patients treated with apixaban 5 mg twice daily.
No differences were noted in the rates of major bleeding,
intracranial bleeding or ischemic stroke between the two
groups.

bleeding risk with addition of antiplatelet medication comes
from the AUGUSTUS study, a multicenter, randomized
trial with a 2x2 factorial design which investigated the use
of a P2Y12 inhibitor in combination with warfarin versus
apixaban and aspirin versus placebo in patients with atrial
fibrillation and acute coronary syndrome or percutaneous
coronary intervention [37]. No patients on hemodialysis
were included and the number of patients with a creatinine
above 1.5 mg/dL was small (creatinine clearance was not
reported). The analysis found an increased risk of bleeding
with the use of a dual antiplatelet regimen in combination
with anticoagulation compared to single antiplatelet agent
combined with anticoagulation with no additional benefit.
Although exploring primarily the risk profile of adding
dual antiplatelet therapy compared to single antiplatelet
therapy, AUGUSTUS provides compelling evidence
for increased bleeding potential with concurrent use of
interacting pharmacokinetic drugs.

The interpretation of retrospective evidence is difficult
given the substantial risk for confounding. An additional
complicating issue is the inability to investigate clinical
variables that may impact the safety of apixaban due to
lack of quality data. Chiefly, analyses of bleeding risk with
DOACs in CKD and HD patients have largely ignored the
interaction of antiplatelets and anticoagulants, which has
recently gained attention in the cardiovascular disease
literature. As previously discussed, CKD and HD patients
are underrepresented in these studies, but the importance
of this issue is underscored by a high percentage of
antiplatelet use (40%-50.6%) in our cohort and that of
others [32,33]. In the RENAL-AF trial, the impact of
antiplatelet therapy on bleeding, despite a high rate of use
(40%), was not explored.

Our group recently reported findings from a retrospective
analysis of bleeding rates in HD patients treated with either
warfarin or apixaban [33]. We found a significantly lower
bleeding propensity with apixaban use alone compared to
warfarin alone, whereas concurrent antiplatelet therapy
markedly reduced the difference (Figure 1). Additionally,
in a multivariate competing risk model, the use of
apixaban alone was again associated with less bleeding
(HR 0.24, 95% CI 0.10-0.55), but this safety advantage
was not observed with concurrent use of apixaban and any
antiplatelet (HR 0.93, 95% CI 0.55-1.56). It is worthwhile
to note that a large database study of non-HD patients
found a lower risk of major bleeding with concomitant
DOAC-antiplatelet use compared to warfarin-antiplatelet
(HR 0.68; 95% CI 0.51-0.91), again raising the question
of whether CKD and HD patients have a different bleeding
risk profile with antithrombotic combinations compared
to other populations [38]. The majority of bleeding in our
cohort (nearly 80% in the apixaban group and 50% in the
warfarin group) originated in the gastrointestinal tract
raising the question of whether the ulcerogenic activity of
antiplatelets underlies the observed difference. Notably,
use of proton pump inhibitors or H2 blockers did not
impact the bleeding risk in our analysis, but this remains
an important avenue for future research.

In non-HD patients, one study found that the concurrent
use of any antiplatelet and apixaban increased the risk of
major bleeding (adjusted odds ratio of 2.01; 95% confidence
interval [95% CI] 1.29-3.11) [34]. A large retrospective
study demonstrated a similarly increased bleeding risk with
addition of aspirin to DOAC (hazard ratio [HR] 1.30; 95%
CI 1.11-1.52) [35]. Another retrospective analysis, however,
found that add-on dual or single agent antiplatelet therapy
to DOAC did not influence the risk in multivariate analysis
[36]. Perhaps the strongest evidence for the increased

Important unknowns remain with regards to the use of
anticoagulant and antiplatelet medication in the advanced
CKD and HD populations. The fundamental question
pertains to the efficacy of anticoagulation in preventing
stroke or venous thromboembolism recurrence in
these cohorts as available data for warfarin and DOACs
is of poor quality and conflicting. One ongoing trial
(NCT03987711) is actively addressing this question by
inclusion of a placebo (no anticoagulation) comparison
arm. Secondly, the safety of DOACs remains to be
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Figure 1: Frequency of major or clinically relevant-non major bleeding with warfarin and apixaban stratified by antiplatelet use
(Modified from [33]).

demonstrated in a large, prospective study and two are
currently ongoing (NCT02933697, NCT03987711).
Importantly, with the current trend in decreasing the
intensity of antithrombotic regimens in patients with
coronary artery disease, antiplatelet therapy should be
included among the randomization criteria of prospective
studies as preliminary findings suggest that their addition
may minimize safety benefits without a concomitant
decrease in thrombotic events. Lastly, with the advent of
betrixaban, a newer DOAC with the lowest documented
renal clearance (15%) [39], it remains to be determined if
this new medication represents a more attractive option
for advanced CKD and HD patients compared to apixaban.

References
1. Koretsune Y, Ikeda T, Kozuma K, Hirano T, Yasaka
M, Kida M, et al. Patient satisfaction after switching
from warfarin to apixaban in patients with nonvalvular
atrial fibrillation: AGAIN study. Patient Preference and
Adherence. 2017;11:1987-1996 (2017)
2. Granger CB, Alexander JH, McMurray JJ, Lopes RD,
Hylek EM, Hanna M, et al. Apixaban versus warfarin in
patients with atrial fibrillation. New England Journal of
Medicine. 2011 Sep 15;365(11):981-92.
3. Connolly SJ, Eikelboom J, Joyner C, Diener HC,
Hart R, Golitsyn S, et al. Apixaban in patients with atrial

Arch Nephrol Ren Stud. 2021
Volume 1, Issue 1

fibrillation. New England Journal of Medicine. 2011 Mar
3;364(9):806-17.
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE,
Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular
atrial fibrillation. New England Journal of Medicine. 2011
Sep 8;365(10):883-91.
5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA,
Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin
in patients with atrial fibrillation. New England Journal of
Medicine. 2013 Nov 28;369(22):2093-2104.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J,
Oldgren J, Parekh A, et al. Dabigatran versus warfarin in
patients with atrial fibrillation. New England Journal of
Medicine. 2009 Sep 17;361(12):1139-51.
7. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J,
Diaz R, Easton JD, et al. Apixaban for reduction in stroke
and other ThromboemboLic events in atrial fibrillation
(ARISTOTLE) trial: design and rationale. American Heart
Journal. 2010 Mar 1;159(3):331-339.
8. Eikelboom JW, O’Donnell M, Yusuf S, Diaz R, Flaker
G, Hart R, et al. Rationale and design of AVERROES:
apixaban versus acetylsalicylic acid to prevent stroke in
atrial fibrillation patients who have failed or are unsuitable
for vitamin K antagonist treatment. American Heart
Journal. 2010 Mar 1;159(3):348-53.

18

Ionescu F, Mansuri S. The Role of Direct Oral Anticoagulants in Advanced Chronic Kidney Disease – Questions and
Future directions. Arch Nephrol Ren Stud. 2021;1(1):16-20.
9. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP,
Rahman M, et al. Chronic kidney disease and prevalent
atrial fibrillation: the Chronic Renal Insufficiency Cohort
(CRIC). American Heart Journal. 2010 Jun 1;159(6):11021107.
10. Reinecke H, Brand E, Mesters R, Schäbitz WR, Fisher
M, Pavenstädt H, et al. Dilemmas in the management of
atrial fibrillation in chronic kidney disease. Journal of the
American Society of Nephrology. 2009 Apr 1;20(4):705711.
11. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber
L, Lane DA, et al. Stroke and bleeding in atrial fibrillation
with chronic kidney disease. New England Journal of
Medicine. 2012 Aug 16;367(7):625-35.
12. Chan KE, Lazarus JM, Thadhani R, Hakim RM.
Anticoagulant and antiplatelet usage associates with
mortality among hemodialysis patients. Journal of the
American Society of Nephrology. 2009 Apr 1;20(4):87281.
13. Van Der Meersch H, De Bacquer D, De Vriese
AS. Vitamin K antagonists for stroke prevention in
hemodialysis patients with atrial fibrillation: A systematic
review and meta-analysis. American Heart Journal. 2017
Feb 1;184:37-46.
14. Masson P, Kelly PJ, Craig JC, Lindley RI, Webster AC.
Risk of stroke in patients with ESRD. Clinical Journal of the
American Society of Nephrology. 2015 Sep 4;10(9):158592.
15. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke,
major bleeding, and mortality outcomes in warfarin users
with atrial fibrillation and chronic kidney disease: a
meta-analysis of observational studies. Chest. 2016 Apr
1;149(4):951-959.
16. Yang F, Chou D, Schweitzer P, Hanon S. Warfarin
in haemodialysis patients with atrial fibrillation: what
benefit?. Europace. 2010 Dec 1;12(12):1666-72.
17. Mavrakanas TA, Garlo K, Charytan DM. Apixaban
versus no anticoagulation in patients undergoing longterm dialysis with incident atrial fibrillation. Clinical
Journal of the American Society of Nephrology. 2020 Aug
7;15(8):1146-54.
18. Baigent C, Herrington WG, Coresh J, Landray MJ,
Levin A, Perkovic V, et al . Challenges in conducting clinical
trials in nephrology: conclusions from a Kidney Disease—
Improving Global Outcomes (KDIGO) Controversies
Conference. Kidney International. 2017 Aug 1;92(2):297305.

Arch Nephrol Ren Stud. 2021
Volume 1, Issue 1

19. Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel
K. Haemostasis in chronic kidney disease. Nephrology
Dialysis Transplantation. 2014 Jan 1;29(1):29-40.
20. Wilke T, Wehling M, Amann S, Bauersachs RM, Böttger
B. Renal impairment in patients with thromboembolic
event: prevalence and clinical implications. A systematic
review of the literature. Deutsche medizinische
Wochenschrift (1946). 2015 Aug 25;140(17):e166-74.
21. Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants
in patients with chronic kidney disease: patient selection
and special considerations. International Journal of
Nephrology and Renovascular Disease. 2017;10:135.
22. Kumar S, Lim E, Covic A, Verhamme P, Gale CP,
Camm AJ, et al. Anticoagulation in concomitant chronic
kidney disease and atrial fibrillation: JACC review topic of
the week. Journal of the American College of Cardiology.
2019 Oct 29;74(17):2204-15.
23. Cheung CY, Parikh J, Farrell A, Lefebvre M, SummaSorgini C, Battistella M. Direct Oral Anticoagulant Use in
Chronic Kidney Disease and Dialysis Patients With Venous
Thromboembolism: A Systematic Review of Thrombosis
and Bleeding Outcomes. Annals of Pharmacotherapy.
2021 Jun;55(6):711-22.
24. Bowie M, Valencia V, Perez-Alvarez I, Tran MH.
Safety analysis of apixaban versus warfarin in patients
with advanced kidney disease. Journal of Thrombosis and
Thrombolysis. 2018 Aug;46(2):246-52.
25. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G,
Lipman ML. Apixaban pharmacokinetics at steady state in
hemodialysis patients. Journal of the American Society of
Nephrology. 2017 Jul 1;28(7):2241-2248.
26. Van den Bosch I, Bouillon T, Verhamme P,
Vanassche T, Jacquemin M, et al. Apixaban in patients
on haemodialysis: a single-dose pharmacokinetics
study. Nephrology Dialysis Transplantation. 2021
May;36(5):884-889.
27. Wang X, Tirucherai G, Marbury TC, Wang J, Chang
M, Zhang D, et al. Pharmacokinetics, pharmacodynamics,
and safety of apixaban in subjects with end‐stage
renal disease on hemodialysis. The Journal of Clinical
Pharmacology. 2016 May;56(5):628-636.
28. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser
SH, Wojdyla DM, Garonzik S, et al . Apixaban versus
warfarin in patients with atrial fibrillation and
advanced chronic kidney disease. Circulation. 2020 Apr
28;141(17):1384-92.

19

Ionescu F, Mansuri S. The Role of Direct Oral Anticoagulants in Advanced Chronic Kidney Disease – Questions and
Future directions. Arch Nephrol Ren Stud. 2021;1(1):16-20.
29. Andò G, Capranzano P. Non-vitamin K antagonist
oral anticoagulants in atrial fibrillation patients with
chronic kidney disease: a systematic review and network
meta-analysis. International Journal of Cardiology. 2017
Mar 15;231:162-169.
30. Chokesuwattanaskul
R,
Thongprayoon
C,
Tanawuttiwat T, Kaewput W, Pachariyanon P,
Cheungpasitporn W. Safety and efficacy of apixaban
versus warfarin in patients with end-stage renal disease:
Meta-analysis. Pacing and Clinical Electrophysiology.
2018 Jun;41(6):627-34.
31. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel
DE, He K, et al . Outcomes associated with apixaban
use in patients with end-stage kidney disease and atrial
fibrillation in the United States. Circulation. 2018 Oct
9;138(15):1519-29.
32. Pokorney SD, Kumbhani DJ, Bhatt DL. RENal
hemodialysis patients ALlocated apixaban versus warfarin
in Atrial Fibrillation-RENAL-AF. Presentation at the
American Heart Association Annual Scientific Sessions
(AHA 2019), Philadelphia, PA. 2019 Nov 16;16.
33. Ionescu F, Cooper C, Petrescu I, George J, Mansuri S.
Safety of apixaban compared to warfarin in hemodialysis
patients: Do antiplatelets make a difference?. European
Journal of Haematology. 2021 May;106(5):689-96.
34. Zhang Y, Souverein PC, Gardarsdottir H, van den
Ham HA, Maitland-van der Zee AH, de Boer A. Risk of
major bleeding among users of direct oral anticoagulants

Arch Nephrol Ren Stud. 2021
Volume 1, Issue 1

combined with interacting drugs: A population-based
nested case–control study. British Journal of Clinical
Pharmacology. 2020 Jun;86(6):1150-64.
35. Said A, Keeney S, Matka M, Hafeez A, George J,
Halalau A. Concomitant use of direct oral anticoagulants
and aspirin versus direct oral anticoagulants alone in
atrial fibrillation and flutter: a retrospective cohort. BMC
Cardiovascular Disorders. 2020 Dec;20: 263.
36. Sotomi Y, Hirata A, Amiya R, Kobayashi T, Hirayama
A, Sakata Y, et al . Bleeding risk of add-on anti-platelet
agents to direct oral anticoagulants in patients with
nonvalvular atrial fibrillation (from 2216 patients in the
DIRECT Registry). The American Journal of Cardiology.
2019 Apr 15;123(8):1293-1300.
37. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro
T, Mehran R, et al . Antithrombotic therapy after acute
coronary syndrome or PCI in atrial fibrillation. New
England Journal of Medicine. 2019 Apr 18;380(16):15091524.
38. Douros A, Renoux C, Yin H, Filion KB, Suissa S,
Azoulay L. Concomitant use of direct oral anticoagulants
with antiplatelet agents and the risk of major bleeding in
patients with nonvalvular atrial fibrillation. The American
Journal of Medicine. 2019 Feb 1;132(2):191-199.
39. Huisman MV, Klok FA. Pharmacological properties
of betrixaban. European Heart Journal Supplements.
2018 May 1;20(suppl_E):E12-15.

20

